Drug intelligence / Profile preview

EPK 004

Development stage: Preclinical
Lead developer: EPIK Biosciences
Modality: Small Molecules

Overview

EPK 004 is a preclinical-stage small molecule combination therapy under development by EPIK Biosciences. It is designed as a synergistic combination of ketamine- and/or dextromethorphan (DXM)-based compounds that target the N-methyl-D-aspartate (NMDA) receptor. The program is being developed for the treatment of various central nervous system and pain disorders, including depression, anxiety disorders, opioid use disorder, post-traumatic stress disorder (PTSD), and chronic and severe pain.

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on EPK 004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPK 004.